Condition

Brain Metastases (1)

Breast Cancer (1)

Breast Neoplasm (1)

HER2-positive Breast Cancer (1)

Metastatic Breast Cancer (1)

Overall Status

Not yet recruiting (2)

Active, not recruiting (1)

Recruiting (1)

Phase

phase 2 (2)

phase 2/phase 3 (1)

phase 3 (1)

Sponsor

Hebei Medical University Fourth Hospital (1)

Second Affiliated Hospital, School of Medicine, Zhejiang University (1)

Shanghai Jiao Tong University School of Medicine (1)

UNICANCER (1)

Collaborator

AstraZeneca (1)

Fondation ARC (1)

Peking University International Hospital (1)

Sun Yat-sen University (1)

Zhejiang University (1)

Study Documents

Intervention Type

drug (4)

biological (1)

Funder Type

Other (4)

Study Type

Interventional (4)

taxanes

Showing 1 - 4 of 4

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

Breast Tumor Trial in China (Epirubicin plus Cyclophosphamide, Taxanes, Taxanes plus Carboplatin)

Recruiting

Breast Neoplasm

Epirubicin plus Cyclophosphamide
+2 more

Fuding, Fujian, China
+26 more

Mar 28, 2022

HER2-positive Breast Cancer, Brain Metastases Trial in Beijing, Guangzhou, Hangzhou (Trastuzumab, Taxanes, Pertuzumab)

Not yet recruiting

HER2-positive Breast Cancer
Brain Metastases

Trastuzumab
+3 more

Beijing, Beijing, China
+2 more

May 28, 2021

Breast Cancer Trial (Pyrotinib, Epirubicin, Cyclophosphamide)

Not yet recruiting

Breast Cancer

Pyrotinib
+4 more

(no location specified)

Feb 27, 2020

Metastatic Breast Cancer Trial in France (AZD2014, AZD4547, AZD5363)

Active, not recruiting

Metastatic Breast Cancer

AZD2014
+18 more

Angers, France
+24 more

Mar 8, 2022